宫颈癌质子治疗的分次间运动稳健性与器官保护潜力
结果显示两种技术靶区稳健性相当,但PBS-PT对危及器官的保护显著更优。
要点
- PBS-PT与VMAT在宫颈癌靶区稳健性上等效。
- PBS-PT四野计划对所有危及器官剂量显著低于VMAT。
- 肠袋V15Gy和骨髓V10Gy在PBS-PT下大幅降低。
核心结论
- 稳健优化的PBS-PT对宫颈癌患者的分次间和分次内变异具有与VMAT等效的靶区稳健性,且危及器官保护显著更优。
研究设计与样本
- 比较了两弧VMAT与稳健优化的二野和四野PBS-PT计划,在计划CT和重复CT上使用摆位和射程不确定性进行稳健评估。
主要发现
- 所有患者骨盆靶区结构的平均体素最小累积剂量在光子和质子技术下均充足,D98 > 95% [91.7-99.3%]。
- 腹主动脉旁区域的平均累积剂量低于所需95%,D98 > 94.4% [91.1-98.2%]。
- PBS-PT四野计划对所有危及器官的剂量显著低于VMAT。
- 肠袋平均V15Gy:VMAT为60% [39-70%],PBS-PT二野为30% [10-52%],四野为32% [9-54%]。
- 骨髓平均V10Gy:VMAT为88% [82-97%],PBS-PT二野为66% [60-73%],四野为67% [60-75%]。
关键数值与推荐
- 靶区覆盖稳健性以体素最小累积剂量D98评估,骨盆靶区要求D98 > 95%,腹主动脉旁区域D98 > 94.4% [91.1-98.2%]但低于95%。
- 危及器官剂量比较包括肠袋V15Gy和骨髓V10Gy,PBS-PT四野计划对所有这些器官剂量显著低于VMAT。
临床怎么用
- 对于宫颈癌放疗,稳健优化的PBS-PT可在保证靶区覆盖稳健性的同时显著降低危及器官剂量,可能减少毒性。
- 临床选择质子治疗时需考虑分次间和分次内运动,采用稳健优化和重复CT评估。
局限性
- 腹主动脉旁区域平均累积剂量未达到95%的D98要求,需关注。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Large-field photon radiotherapy is current standard in the treatment of cervical cancer patients. However, with the increasing availability of Pencil Beam Scanning Proton Therapy (PBS-PT) and robust treatment planning techniques, protons may have significant advantages for cervical cancer patients in the reduction of toxicity. In this study, PBS-PT and photon Volumetric Modulated Arc Therapy (VMAT) were compared, examining target coverage and organ at risk (OAR) dose, taking inter- and intra-fraction motion into account. MATERIALS AND METHODS: Twelve cervical cancer patients were included in this in-silico planning study. In all cases, a planning CT scan, five weekly repeat CT scans (reCTs) and an additional reCT 10 min after the first reCT were available. Two-arc VMAT and robustly optimised two- and four-field (2F and 4F) PBS-PT plans were robustly evaluated on planCTs and reCTs using set-up and range uncertainty. Nominal OAR doses and voxel-wise minimum target coverage robustness were compared. RESULTS: Average voxel-wise minimum accumulated doses for pelvic target structures over all patients were adequate for both photon and proton treatment techniques (D98 > 95%, [91.7-99.3%]). Average accumulated dose of the para-aortic region was lower than the required 95%, D98 > 94.4% [91.1-98.2%]. With PBS-PT 4F, dose to all OARs was significantly lower than with VMAT. Major differences were observed for mean bowel bag V15Gy: 60% [39-70%] for VMAT vs 30% [10-52%] and 32% [9-54%] for PBS-PT 2F and 4F and for mean bone marrow V10Gy: 88% [82-97%] for VMAT vs 66% [60-73%] and 67% [60-75%] for PBS-PT 2F and 4F. CONCLUSION: Robustly optimised PBS-PT for cervical cancer patients shows equivalent target robustness against inter- and intra-fraction variability compared to VMAT, and offers significantly better OAR sparing.
引用
- Gort EM, Beukema JC, Matysiak W, et al. Inter-fraction motion robustness and organ sparing potential of proton therapy for cervical cancer. Radiother Oncol. 2020. PMID: 32956707. doi:10.1016/j.radonc.2020.09.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。